Carvolix

Affluent Medical, established in Aix-en-Provence, France, is a medical technology company focusing on the development of minimally invasive implants for the cardiovascular and urology sectors. Founded in 2011 by Michel Finance and Léopold Séguéla through the merger of four startups (Epygon, Kalios, Kardiozis, and Artus), the firm aims to address significant unmet medical needs in these fields. Michel Finance, serving as CEO, brings extensive experience from the medical device industry, having held leadership roles at companies like Sorin Group and St. Jude Medical. Co-founder Léopold Séguéla is a cardiac surgeon, providing deep clinical and anatomical expertise that directly informs the company's product development.

The company's business model centers on developing and bringing to market a portfolio of advanced medical devices. Affluent Medical generates revenue through the sale of these products once they receive regulatory approval and are commercialized. Its target clients are hospitals and surgical centers, with the ultimate beneficiaries being patients suffering from specific cardiovascular and urological conditions. The company operates in the global medical device market, with an initial focus on Europe. A significant milestone was its initial public offering (IPO) on the Euronext Paris exchange in 2021, which was intended to finance the clinical development of its key products.

Affluent Medical's product pipeline includes several devices currently in clinical or preclinical stages. For mitral valve disease, the company is developing Epygon, a transcatheter mitral valve designed to mimic the heart's natural blood flow, and Kalios, an adjustable ring for mitral valve repair that allows for non-invasive postoperative adjustments. In the vascular domain, Kardiozis is an implant designed to prevent endoleaks following abdominal aortic aneurysm repair. For urology, Artus is presented as the first electronically activated artificial urinary sphincter to treat stress urinary incontinence in both men and women.

Keywords: MedTech, cardiovascular implants, urological devices, minimally invasive surgery, mitral valve repair, transcatheter mitral valve, artificial urinary sphincter, abdominal aortic aneurysm, endoleak prevention, medical technology, surgical implants, cardiac surgery, urology, clinical trials, medical device development, public company, Euronext, Aix-en-Provence, Michel Finance, Léopold Séguéla